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SUMMARY
Treatment of rats with desipramine (DM1) has been shown to
down-regulate /3-adrenergic receptor-stimulated adenylate cy-
clase and reduce the Bmax of /3-adrenergic receptors in some
brain areas. Recent reports have indicated that the down-regu-
lation in the number of (3-adrenergic receptors following DM1
treatment does not occur if the serotonin system has been
impaired following parachlorophenylalanine (PCPA) or 5,7-dihy-
droxytryptamine injection. We have previously shown that
[3H]dihydroalprenolol ([3H]DHA), the most commonly used rath-
oligand to measure central nervous system /3-adrenergic recep-
tors, labels another site under normal experimental procedures,
in addition to the /3-adrenergic receptors. This second site
has some pharmacological characteristics of the 5-hydro-
xytryptaminelB receptor. The depletion of serotonin following
PCPA injection was indeed able to prevent the down-regulation
of [3H]DHA binding sites after DM1 injection. However, PCPA
alone increased the density of [3H]DHA binding sites. If the
nonlinear, least squares, curve-fitting program LIGAND was al-
lowed to define [3H]DHA nonspecific binding or if the more
selective (3-adrenergic receptor radioligand [3H]CGP-1 21 77 was
used, the Bmax Of /3-adrenergic receptors was not changed after
PCPA injection. Importantly, PCPA did not prevent (3-adrenergic
receptor down-regulation following DM1 treatment. The blockade
of 5-hydroxytryptamine2 receptors, via ketanserin administration,
during DM1 treatment did not change the response of (3-adrener-
gic receptors. Furthermore, if LIGAND was used to define the
nonspecific binding of [3H]DHA, the down-regulation of (3-adre-
nergic receptors was significant 24 hr after a single DM1 injection.
The same rapid down-regulation was demonstrated with [3H]
CGP-1 21 77. However, if [3H]DHA was used to label (3-adrenergic
receptors in the “typical” manner (nonspecific binding defined by
1 0 tM alprenolol), a decrease in the number of (3-adrenergic
receptors was significant only after seven daily DM1 injections.
These data demonstrate that the use of [3H]DHA to measure /3-
adrenergic receptors can be misleading, because changes in its
second binding site can conceal the changes occurring in [3-
adrenergic receptors. Moreover, these results suggest that a
similarity in the time course of action of DM1 cannot be used to
support the hypothesis that its therapeutic antidepressant action
is related to (3-adrenergic receptor down-regulation.
Many authors have reported that a common effect of the
chronic treatment of rats with antidepressant therapies is the
desensitization of the /3-adrenergic receptor stimulation of
adenylate cyclase, coupled with a reduction in the number of
/3-adrenergic receptors in some brain regions. These effects
have become a cornerstone in the development of the biogenic
amine hypothesis of depression (1), in part because of the
apparent similar time course for these biochemical effects and
the gradual development of a therapeutic response to antide-
pressant treatment (1-4). Tricyclic antidepressants, such as
DM1, inhibit the reuptake of both norepinephrine and sero-
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tonin. A number of recent papers have suggested that the
decrease in /3-adrenergic receptors is dependent on the integrity
of serotonergic as well as noradrenergic synaptic transmission.
For example, depletion of serotonin with the tryptophan hy-
droxylase inhibitor PCPA (5, 6) or lesion of serotonergic neu-
rons with the neurotoxin 5,7-dihydroxytryptamine (7, 8) is
reported to block the ability of desipramine to decrease (3-
adrenergic receptors measured with [‘H]DHA. However, some
authors have reported a dissociation between the blocking effect
of the serotonin lesion on DM1-induced (.3-adrenergic receptor
down-regulation and the development of the desensitization of
the /3-adrenergic receptor-stimulated adenylate cyclase system
after chronic DM1 administration (8, 9).
In the accompanying paper, we have demonstrated that the
most widely used /3-adrenergic receptor radioligand, [H]DHA,
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labels a second binding site, with some pharmacological simi-
larities to the 5HT,, receptor (10). Thus, modifications of the
serotonergic systems could potentially alter the binding of [H]
DHA to its second binding site rather than, or as well as, to /3-
adrenergic receptors, complicating the interpretation of the
experiments.
For this study, we have examined the influence of serotonin
depletion following PCPA treatment or the effect of prolonged
5HT:. receptor blockade on the ability of DM1 to down-regulate
/3-adrenergic receptors, using a selective ligand for (3-ad.renergic
receptors, [H]CGP-12177, and utilizing computer analysis of
[‘HIDHA binding with the program LIGAND (11), which en-
ables the selective labeling of /3-adrenergic receptors by [H]
DHA to be quantified (10). In these studies, we also determined
the time course of the down-regulation of /3-adrenergic recep-
tors by DM1, because there is some controversy in the literature
as to the ability of the acute versus chronic administration of
DM1 to down-regulate /3-adrenergic receptors (3, 4, 12, 13),
which could have resulted from a differential effect of DM1 on
the /3-adrenergic receptor and “serotonergic” components of
[H]DHA binding.
Materials and Methods
Animals and tissue preparation. Adult male Sprague-Dawley
rats (Charles River, Wilmington, MA), weighing 200-300 g, were used
throughout the experiments; they were housed in group cages under
standard conditions ( 12-hr light-dark cycle) with free access to food
and water. The animals were killed by decapitation (between 10 am.
and 1 p.m.) and the brains were immediately removed into ice-cold
saline. Brain regions were rapidly dissected, placed into plastic vials,
frozen on dry ice, and stored at -70’ until the day of the experiment.
Rat cerebral cortices, hippocampi, or striata were homogenized using a
Tekmar Tissuemizer (setting of 6 for 15 sec) in 50 volumes of cold 50
mM Tris HCI (pH 7.7 at 25) and were centrifuged three times at
35,000 x g for 20 mm.
Drug treatments. In time course experiments, DM1 was injected
at a dose of 15 mg/kg, intraperitoneally, daily. When the interaction
of DM1-induced (3-adrenergic receptor down-regulation and 5HT2 re-
ceptor blockade was studied, DM1 was injected intraperitoneally, at 10
mg/kg, twice a day, whereas ketanserin tartrate was either injected
intraperitoneally at 5 mg/kg, twice a day, or released by Alzet osmotic
minipumps at a dose of 0.34 mg/kg/hr. When minipumps were used,
the rats were anesthetized with methoxyflurane (Metofane; Pitman-
Moore Inc.) and Alzet osmotic minipumps (model 2001) were placed
subcutaneously in the scapular region of the animal. When the influ-
ence of serotonin depletion was investigated, the dosage of PCPA was
350 mg/kg, intraperitoneally, daily for the first 3 days and 125 mg/kg
every other day from day 4 through day 1 1 . Control animals received
an injection ofsaline solution (0.9% NaCl). DM1 was administered (15
mg/kg, intraperitoneally, daily) for 8 days to either saline- or PCPA-
treated rats, starting from day 4. All animals were killed 24 hr after
the last injection.
9.Adrenergic receptor binding. Two different ligands were used
to measure 1-adrenergic receptor binding, [‘H]DHA (specific activity,
52.3-95 Ci/mmol; New England Nuclear, Boston, MA) and [‘H]CGP-
12177 (specific activity, 53 Ci/mmol; Amersham Corporation, Arlington
Heights, IL). Binding was performed in borosilicate disposable tubes.
The final assay volume of 2 ml consisted of 100 il of radiolabeled
ligand, 100 gl of alprenolol (final concentration, 10 MM) to measure the
“nonspecific” binding, competing drug as required, or incubation buffer
(50 mM Tris.HC1, pH 7.7 at 25), 800 zl of incubation buffer, and 1 ml
of membrane suspension containing 6 mg of wet weight tissue, which
was added at the start of the incubation.
The test tubes were incubated for 30 mm at 37 , then filtered under
vacuum through Whatman GF/C filters, and washed three times with
5 ml of ice-cold Tris buffer, using a modified Brandel cell harvester.
Filters were placed in plastic mm-scintillation vials and 5 ml of Ecol-
ume (ICN Biomedicals, Inc.) were added. Radioactivity trapped on the
filters was counted using a Beckman LS 5000 TD scintillation counter
at an efficiency of 43%.
In saturation experiments, [‘H]DHA was usually incubated in a
concentration range ofO.2 to 6.0 nM, except in time course experiments,
where it was incubated in a concentration range of 0.2 to 8.0 nM.
Saturation curves of [‘H]CGP-12177 were performed in a concentration
range of 0.025 to 2.0 nM, whereas in competition studies 0.2 nM [‘H]
CGP-12177 was used.
5HT2 receptor binding. [‘H]Ketanserin (specific activity, 61.5 Ci/
mmol, New England Nuclear) was used to measure 5HT2 receptors,
following the method previously reported (14). Briefly, individual fron-
tal cortices were homogenized as described before and the final resus-
pension was made in ice-cold 50 mM Tris buffer (pH 7.7 at 25’).
Saturation studies were carried out using six concentrations of [‘H]
ketanserin (0.1-4.0 nM), which were incubated with 4 mg of original
wet weight of frontal cortex in 2.5 ml of assay buffer, in the absence or
presence of 500 nM cinanserin, which was used to define nonspecific
binding to 5HT2 receptors. Specific binding represented 75% of total
binding at 0.5 nM [‘H]ketanserin. The incubation was carried out for
30 mm at 37’ before the reaction was stopped by filtration over
Whatman GF/C glass fiber filters. Filters were washed quickly with
three 5-ml portions of ice-cold 50 mM Tris buffer and were counted in
5 ml of Ecolume by scintillation counting of an efficiency of 43%.
Tryptophan 5-hydroxylase activity. The activity of the enzyme
tryptophan 5-hydroxylase was measured in rat striatum, following a
modification of the fluorimetric method of Gal and Patterson (15).
Briefly, rat striata were homogenized in HEPES buffer (50 mM
HEPES, 20 mM dithiothreitol, 2 mM CaCI2, 50 sM ferrous ammonium
sulfate, and 0.1 mM phenylmethylsulfonyl fluoride, pH 7.4) with a
motor-driven Teflon pestle and were centrifuged at 12,000 rpm for 10
mm. An aliquot of the supernatant was added to the assay buffer (30
mM KH2PO4, 6 mM 2-aminoethylisothiouronium bromide, 0.2 mM
pargyline, 16 sM ferrous ammonium sulfate) with 40 g of catalase, 0.2
mM L-tryptophan, and 0. 1 mM DL-6-methyl-5,6,7,8-tetrahydropterine.
The samples either were incubated at 37’ or were kept on ice (tissue
blanks). A standard curve was prepared separately using L-5-hydroxy-
tryptophan (0-1100 ng) dissolved in the assay buffer. After an incu-
bation with 0.3 mg of ortho-phthaldialdehyde, the formation of L-5-
hydroxytryptophan was measured by fluorescence spectroscopy (Per-
kin-Elmer LS-5 spectrophotometer) with 360-370 nm as excitatory
wavelength and 470-505 nm as emission wavelength.
Data analysis. The weighted, nonlinear, least squares, iterative
curve-fitting program LIGAND was used for the analysis of saturation
and competition experiments ( 1 1 ). Saturation experiments were ana-
lyzed either by fitting the “specific” binding (defined as the difference
between total binding and “nonspecific” binding delineated by 10 MM
aiprenolol) or by fitting the total binding, with the nonspecific binding
being allowed to float and fitted by the program as a linear function of
‘H-ligand concentration. All saturation and competition studies were
initially analyzed with a one-site model (i.e., one saturable binding
site); the data were then analyzed according to a two-site model (i.e.,
two distinct saturable binding sites of different affinities) and the
results of this curve fitting was statistically compared with a one-site
model by an F test. The two-site model was accepted if the fit was
significantly better (p < 0.05) with respect to the one-site analysis.
LIGAND also allows for the simultaneous analysis of multiple compe-
tition curves for the same ligands, which provides more information
for the accurate calculation of binding parameters.
An ANOVA test was used in the statistical analysis of the experi-
ments and comparison between any two groups was made by the
Dunnett t test. When comparisons were made between assays run in
parallel or between different assay conditions (nonspecific binding
defined by 10 MM alprenolol or by LIGAND), comparisons were also
made by paired Student t test.
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Drugs. The following drugs were donated: ketanserin tartrate (Jans-
sen Pharmaceutica, Beerse, Belgium), ICI 89,406 (Imperial Chemical
Industries, Wilmington, DE), DM1 (Merrel Dow Pharmaceuticals Inc.,
Cincinnati, OH), and cinanserin HC1 (Squibb & Sons Inc., Princeton,
NJ).
The following compounds were purchased: l-alprenolol and PCPA
HC1, (Sigma, St. Louis, MO) and CGS-12066B (Research Biochemicals
Incorporated, Natick, MA).
Results
Time Course of -Adrenergic Receptor Down-Regulation
following DM1 Treatment
Rats were treated with a single daily injection of either saline
or DM1 for 1, 2, 4, or 7 days and were killed 24 hr after the last
injection. The data from the saline-treated rats were pooled,
because they were not statistically different from each other,
for comparisons with the DM1-treated rats. Utilizing the corn-
mon procedure of defining nonspecific binding of [:tH]DHA
with the j9-adrenergic receptor antagonist alprenolol, it can be
seen in Fig. 1 that a significant decrease (-19.4%) in the Bm,,
of [‘H]DHA binding to rat cerebral cortex membranes did not
occur until after a ‘7-day DM1 treatment. However, as we show
in the accompanying paper, [:H1DHA also labels another bind-
ing site and alprenolol inhibits [:H]DHA binding to this site
(10). If the saturation data for [‘H]DHA binding were analyzed
using the nonlinear, least squares, iterative curve-fitting pro-
cedure LIGAND, allowing the computer program to define
nonspecific binding as a linear function of :H4igand concen-
Q)
U)
U)
C)
0
E
E
0
0
I
5.)
Fig. 1. Time course of the effect of DM1 treatment on [3H]DHA binding
to rat cerebral cortex membranes. Saturation curves of [3HJDHA (the
concentration range was 0.2 to 8.0 nM) were analyzed by LIGAND,
defining its nonspecific binding either with 10 MM alprenolol (0) or having
the ‘nonspecific’ binding determined by the computer program as a linear
function of 3H-ligand concentration (U). The B, (frnol/mg of tissue) for
control, alprenolol-defined, [3HJDHA binding was 1 3.43 ± 0.37. The
control density of [3HJDHA binding (6.30 ± 0.26 fmol/mg of tissue) was
significantly lower (p < 0.001) when nonspecific binding was defined by
LIGAND. No significant changes in Kd values were detected following
DM1 treatments; in saline-treated animals, the K,, of [3H]DHA was 1.81
± 0.08 nM when nonspecific binding was defined by 10 MM alprenolol,
which was significantly greater than the K of 0.74 ± 0.06 n obtained
when the nonspecific binding was determined by LIGAND. ap < 0.01
versus saline-treated rats with nonspecific binding defined by 10 MM
alprenolol (Dunnett t test). bp < 0.001 versus saline-treated rats when
nonspecific binding was determined by 1 0 MM alprenolol (paired t test).
Cp < 0.05 versus saline-treated rats with nonspecific binding defined by
LIGAND (Dunnett t test). 51p < 0.01 versus saline-treated rats with
nonspecific binding defined by LIGAND (Dunnett t test).
tration, a significantly lower B,,,. was obtained in control
animals, more closely representing the true [3-adrenergic recep-
tor number. With the nonspecific binding of [H]DHA defined
by LIGAND in this way, it can be seen that the specific (3-
adrenergic receptor binding of [H]DHA was decreased signif-
icantly 24 hr after a single injection of DM1 (-23). Indeed,
although the reduction following a 7-day treatment with DM1
was somewhat greater (-37%), this decrease was not signifi-
cantly greater than the decrease seen after a single injection.
All of these changes in B ,,,,, . occurred without significant
changes in Kd values.
We have previously determined that the ligand [H]CGP-
12177 is a more specific ligand for /3-adrenergic receptors.
Similar Bma. values were obtained ( 10) whether nonspecific
binding was defined by alprenolol or by LIGAND. Fig. 2 dem-
onstrates that the B,5, of [3-adrenergic receptors labeled by
[‘H]CGP-12177 was decreased in rat cerebral cortex 24 hr after
a single injection of DM1. In the case of this ligand, a time
course in the reduction of [3-adrenergic receptors following DM1
treatment for up to 7 days was apparent, with the decrease at
7 days (-34.1%) being significantly greater than the decrease
seen at 1 (-9.3%) or 2 days (-19.6%) of treatment. However,
a single acute injection of DM1, with the animal being sacrificed
2 hr later, showed no decrease in [3-adrenergic receptor number
(saline = 5.40 ± 0.10 versus acute DM1 = 5.36 ± 0.16 fmol/mg
of tissue). There was no change in the affinity of [ H]CGP-
12177 for /3-ad.renergic receptors after any of the DM1 treat-
ments. The same pattern of /3-adrenergic receptor down-regu-
lation after DM1 treatment was observed in rat hippocampal
membranes (Fig. 2). However, no significant change in [3-
Days of DM1 treatment
Fig. 2. Time course of the effect of DMI treatment on [3H]CGP-1 2177
binding to rat cerebral cortex and hippocampus membranes. [3H]CGP-
121 77 saturation curves for cerebral cortex (0) and hippocampus ()
membranes were analyzed by LIGAND with nonspecific binding defined
by 10 MM alprenolol. The control B, value (fmol/mg of tissue) in cerebral
cortex (mean ± SE of at least six separate determinations) was 5.40 ±
0.1 0. No significant changes in Kd values from those in the saline-treated
rats (0.1 3 ± 0.01 nM) were observed following DM1 treatments. In rat
hippocampal membranes, the percentages (mean ± SE of five or six
separate determinations) of [3H]CGP-1 21 77 binding with respect to
saline-treated rats (Bma 2.55 ± 0.1 0 fmol/mg of tissue) were: OMI, 1-
day = 88.1 ± 3.1%e; DM1, 2-day = 85.7 ± 3.8%8; DM1, 4-day = 75.0 ±
6.1%”; and DMI, 7-day = 65.9 ± 3.1%c. ap < 0.05 versus saline-
treated rats (Dunnett t test). bp < 0.01 versus saline-treated rats (Dunnett
t test). Cp < 0.05 versus DM1 1-day-treated rats (Dunnett t test). #{176}p<
0.01 versus DM1 1-day- and p < 0.05 versus DM1 2-day-treated rats
(Dunnett t test).
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adrenergic receptors was found after a 7-day treatment with
the antidepressant in striatal membranes from the same rats
(saline = 7.10 ± 0.37 versus DM1 = 6.33 ± 0.30 fmol/mg of
tissue).
[H]CGP-12177 has similar affinities for the [3- and the /32-
adrenergic receptor subtypes (16). In order to investigate the
effect of DM1 treatment on (3- and /32-adrenergic receptor
subtypes individually, competition curves of the semiselective
/3-adrenergic receptor antagonist IC! 89406 (17) for [H]CGP-
12177 binding to cortical membranes were analyzed by the
computer program LIGAND into two sites, the higher affinity
site representing IC! 89406 binding to /3-adrenergic receptors
(K, = 1.12 ± 0.10 nM) and the lower affinity site representing
IC! 89406 binding to /32-adrenergic receptors (K, = 126.7 ± 11.7
nM). Rats were treated for 7 days with DM1 and, as shown in
Fig. 3, a significant 29% decrease in /3, -adrenergic receptors
occurred, with no significant change in [32-adrenergic receptors.
Investigation of the Role of Serotonin in the Down-
Regulation of [3-Adrenergic Receptors by DM1
Influence of 5HT2 receptor blockade on the DM1-in-
duced 9-adrenergic receptor down-regulation. In order
to investigate whether 5HT2 receptors could be involved in the
down-regulation of /3-adrenergic receptors, rats were concur-
rently treated with DM1 and the 5HT2 receptor antagonist
ketanserin for a 7-day period. Ketanserin was either adminis-
tered by intraperitoneal injection, at the same time as DM1 was
administered, or it was released continuously by implanted
osmotic minipumps (see Materials and Methods for details).
As can be seen in Table 1, treatment with ketanserin alone
(either by intraperitoneal injection or by minipump) did not
affect the density of (1-adrenergic receptors measured by [‘H]
CGP-12177. The resolution of IC! 89406 competition curves
0
(1)
(I)
a)
E
0
E
(5
E
1:
cL
(9
0
I
C.)
Drug treatment
Fig. 3. Effect of 7-day DM1 treatment on (3-adrenergic receptor subtypes
in rat cerebral cortex membranes. The density of total (3-adrenergic
receptors (D) was determined by saturation experiments of [3H]CGP-
121 77 binding with nonspecific binding defined by 10 MM alprenolol and
analyzed by LIGAND. The resolution of (3-adrenergic receptors into (3,-
(0) and (32- 4 adrenergic receptor subtypes was obtained from analyzing
the competition curves of the semiselective (3-adrenergic receptor sub-
type antagonist lCl 89406 for 0.2 flM [3H]CGP-12177 binding. The
competition curves were analyzed by LIGAND using the K,, of [3H]CGP-
121 77 for the total (3-adrenergic receptor population obtained from
saturation experiments. The competition curves were best fitted to a
two-site model, with the K, for the higher affinity site, representing (3,-
adrenergic receptors, being 1 .1 2 ± 0.10 nM and the K, for the lower
affinity site, representing (32-adrenergic receptors, being 1 26.7 ± 11.7
nM. 8p < 0.01 versus saline-treated rats (Dunnett t test).
TABLE 1
Density of 9-adrenergic receptors, measured by [3H]CGP-12177, in
rat cerebral cortex membranes following chronic treatment (7 days)
with DM1: effect of concomitant ketanse#{241}nadministration either by
intrapentoneal injection (IP) or by osmotic minipump implantation
(MP)
The density of total J-adrenergic receptors (, + i12) was determined by saturation
experiments of [3HICGP-1 21 77 binding with nonspecific binding defined by 10 MM
aiprenolol analyzed by LIGAND. No significant change was detected in K,, values
(saline = 0.1 4 ± 0.03 nM). The resolution of 1-adrenergic receptors into ,- and l2
adrenergic receptors was obtained from competition curves of the semiselective f-
adrenergic receptor subtype antagonist ICI 89406 for 0.2 nM 13H]CGP-1 2177
binding. The complete competition curves were analyzed by the computer program
LIGAND for two sites using the K,, of [3H)CGP-1 21 77 for f-adrenergic receptors
obtained from saturation experiments. Nonspecific binding was defined by LIGAND.
Density
Treatment
3,+J2 Ji
(mo//mg of tissue
Saline 5.32 ± 0.23 4.41 ± 0.28 0.94 ± 0.14
DM1 3.88 ± o.i9 3.11 ± 0.21’ 1.01 ± 0.14
Ketansenn (IP) 5.55 ± 0.20 4.86 ± 0.32 1.07 ± 0.15
DM1 + ketanserin (IP) 3.98 ± 0.13” 3.11 ± 0.16” 0.99 ± 0.16
Ketansenn (MP) 5.59 ± 0.1 7 4.64 ± 0.30 1 .00 ± 0.09
DM1 + ketanserin (MP) 3.83 ± 0.15c 2.54 ± 0.12” 1.02 ± 0.14
C p < 0.01 versus saline-treated animals (Dunnett t test).
a  <  versus saline- or ketanserin (IP)-treated animals (Dunnett t test).
 p < 0.01 versus saline- or ketansenn (MP)-treated animals (Dunnett t test).
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Fig. 4. Time course of DM1 treatment on 5HT2 receptor binding in rat
frontal cortex. The density of 5HT2 receptors was determined by satu-
ration experiments with [3H]ketanserin. The control Bma. was 21 .07 ±
0.94 fmol/mg of tissue. No significant change in Kd values was detected
with the different treatments (K,, in saline-treated rats was 0.53 ± 0.06
nM). 8p < 0.01 versus saline-treated rats (Dunnett t test).
for [‘H]CGP-12177 binding indicated that neither f3-adrenergic
receptor subtype was altered by ketanserin treatment. The
treatment of rats with ketanserin did not prevent the down-
regulation of /3-adrenergic receptors elicited by DM1. Although
the combined treatment with ketanserin (via minipump) and
DM1 produced a somewhat larger decrease in /3-adrenergic
receptors, this effect was not statistically significant (p > 0.05).
Prolonged treatment with DM1 has also been reported to
down-regulate the number of 5HT2 receptors in rat cerebral
cortex (18). We investigated the time course of this modifica-
tion and the effect of a concomitant administration of ketan-
serin on the adaptive changes of 5HT2 receptors following DM1
administration. Fig. 4 shows that a significant reduction in the
number of 5HT2 receptors measured with [‘H]ketanserin was
evident after 4 days of treatment with DM1 (-25%). This
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. p < 0.001 versus saline-treated group when nonspecific binding was defined
by 1 0 5M alprenolol (paired t test).
b ,,< 0.05 versus saline-treated rats (paired t test).
‘ p < 0.01 versus saline-treated rats (Dunnett t test).
d ,, < 0.05 versus saline- or PCPA-treated rats (Dunnett t test)
a)
U)
U)
C)
E
0
E
E
c’J
15
I
;io
(5 ++
C  .1 i.I 1
SALINE DM1 PCPA DMI+PCPA
Drug treatment
Fig. 5. Rat stnatal tryptophan hydroxylase activity following DM1 and/or
PCPA treatment. The values are the mean ± standard error of six
separate determinations. p < 0.001 versus saline-treated rats (Dunnett
t test).
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TABLE 2
Density of 5HT2 receptors in rat frontal cortex after DM1 treatment:
effect of concomitant ketanserin administration either by
intraperitoneal injection (IP) or by osmotic minipump implantation
(MP)
Rats were sacrificed 24 hr after the last injection of DM1. The B,, of 5HT2 receptors
was determined by saturation experiments with [3H]ketanserin. with nonspecific
binding defined by 500 tiM cinanserin. No differences in K, values (0.54 ± 0.05 nM)
were detected among the experimental groups.
Drug treatment B,,.
fmol/mg of t,ssue
Saline 21 .07 ± 0.94
DM1 15.67 ± 0.74e
Ketansenn (IP) 1 5.50 ± 0.66a
DM1 + ketanserin (IP) 13.75 ± 0.83a
Ketanserin (MP) 1 5.81 ± 0.80
DM1 + ketanserin (MP) 13.19 ± 0.82a
a  <  versus saline-treated rats (Dun nett t test).
reduction was not significantly different from that observed
after the 7-day treatment with the antidepressant. As has been
reported previously (19), Table 2 indicates that ketanserin
itself, either following intraperitoneal injection or minipump
implantation, was able to down-regulate the number of 5HT2
receptors. However, this effect was not additive with the DM1-
induced down-regulation; although the rats treated with the
two drugs demonstrated a larger reduction in [‘H]ketanserin
B,,,,,, this effect was not significantly greater than that produced
by DM1 or ketanserin administered alone.
Effect of serotonin depletion on DM1-induced down-
regulation of fl-adrenergic receptors. Rats received a prior
treatment with PCPA (350 mg/kg daily, intraperitoneally) for
3 days before the treatment with DM1 for 8 days was begun.
During the DM1 treatment, PCPA administration was main-
tamed by injection of 125 mg/kg every other day. The rats were
sacrificed 24 hr after the last DM1 injection. Fig. 5 shows that
the PCPA treatment reduced striatal tryptophan hydroxylase
activity by more than 90%. The co-treatment with DM1 and
PCPA produced a similar decrease in tryptophan hydroxylase
activity, whereas DM1 alone did not change the activity of the
enzyme.
/3-Adrenergic receptors were quantified using either [:H]
DHA or [:H]CGp12177 When binding was measured using
[‘H]DHA in the typical manner, with nonspecific binding de-
fined by 10 MM alprenolol, it can be seen in Table 3 that the
DM1 treatment alone significantly reduced “specific” binding
by 14%. PCPA treatment alone significantly increased binding
by 15% and the co-treatment with DM1 and PCPA produced
binding levels that were not significantly different from those
in the saline-treated animals. However, if [H]DHA binding to
(3-adrenergic receptors was defined by the computer program
LIGAND, with nonspecific binding determined as a factor
proportional to ‘H-ligand concentration, the following obser-
vations were made: DM1 significantly reduced (3-adrenergic
receptor binding by 38%; PCPA treatment did not affect (3-
adrenergic receptor binding; and the co-treatment with DM1
and PCPA produced a significant decrease in (3-adrenergic
receptors of 20%, which was not significantly different from
that produced by DM1 alone. Similarly, as shown in Fig. 6,
when f3-adrenergic receptors were measured specifically with
TABLE 3
[3H]DHA binding to rat cerebral cortex membranes after a
prolonged treatment with DM1 (8 days): effect of serotonin
depletion following PCPA injection
Rats were killed 24 hr after the last DM1 injection. Nonspecifc binding for 3HJDHA
(concentration range of 0.2 to 6.0 nM) was either defined by 10 ,AM alprenolol or
defined by the computer program LIGAND. No significant change was detected in
K5 values following the drug treatment.
B,,..
Treatment Nonspecific bindingdetned by Nonspecific binding def,ned by
lO5Malprenolol LIGAND
fmol/mg of t,ssue
Saline 10.78 ± 0.54 5.92 ± 0.50
DM1 9.25 ± 0.43” 3.66 ± 0.08
PCPA 12.45 ± 0.50” 5.74 ± 0.13
DM1 + PCPA 10.98 ± 0.59 4.71 ± 0.33”
cL
(9
0
I
C.)
SALINE DM1 PCPA DMI+PCPA
Drug treatment
Fig. 6. Effect of serotonin depletion following PCPA injection of[3HJCGP-
121 77 binding to rat cerebral cortex membranes after a chronic treatment
with DM1 (8 days). [3H]CGP-1 21 77 saturation curves were analyzed by
LIGAND with nonspecific binding defined by 10 MM alprenolol. The
measured B,,,, values (fmol/mg of tissue) were: saline = 5.14 ± 0.10;
DM1 = 3.64 ± 0.lOa; PCPA = 5.58 ± 0.10; and DM1 + PCPA = 4.08 ±
0.27”. No changes in Kd values of [3HJCGP-1 21 77 were detected (saline
= 0.099 ± 0.001 nM). ap < 0.01 versus saline-treated rats (Dunnett
test). bp < 0.01 versus saline or PCPA-treated rats (Dunnett t test).
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[H]CGP-12177, with nonspecific binding defined by 10 MM
alprenolol, DM1 treatment produced a 29% reduction in [3-
adrenergic receptor B,,,,. and PCPA did not significantly alter
/3-adrenergic receptor binding, whereas the co-treatment with
PCPA and DM1 produced a significant 21% decrease in /3-
adrenergic receptor B ,,,,, , which was not significantly different
from that elicited by DM1 treatment alone. None of the treat-
ments altered the affinity of the ‘H-ligands for their binding
sites.
Discussion
/3-Adrenergic receptors were one of the first types of central
nervous system neurotransmitter receptor to be studied with
radioligand binding techniques (20). [‘H]DHA was used as the
radioligand for their initial characterization and has remained
the most popular ligand for the study of these receptors. Nu-
merous reports have demonstrated that the chronic treatment
of rats with antidepressants leads to the down-regulation of /3-
adrenergic receptors as labeled by [‘H]DHA, as well as the
reduction in the ability of (3-adrenergic agonists to stimulate
adenylate cyclase activity ( 1-4). However, differences have
been noticed in the time course for these two events (3, 4, 12,
13). Similarly, manipulations ofserotonergic systems have been
reported to block the ability of antidepressants to down-regu-
late /3-adrenergic receptor binding (5-9), although in some
reports, paradoxically, the reduced sensitivity of adenylate cy-
clase to stimulation by (3-adrenergic agonists was unaffected (8,
9).
Our recent studies have demonstrated that [‘H]DHA labels
an additional site besides (3-adrenergic receptors and that the
separation of these two sites cannot be adequately obtained
with the drugs currently used to define [‘H]DHA nonspecific
binding (10). The additional [‘H]DHA site has some of the
pharmacological characteristics of a serotonergic binding site
and may be identified with the 5HTH serotonin receptor sub-
type (10). A possible explanation for the differential effects of
serotonergic manipulations on “/3-adrenergic receptors” labeled
by [‘H]DHA and (3-adrenergic stimulation of adenylate cyclase
by DM1 is thus suggested, because such manipulations may
modulate the serotonergic and (3-adrenergic receptor compo-
nents of I H]DHA binding differently.
We have demonstrated that it is possible to use [‘H]DHA to
label 3-adrenergic receptors selectively, if the binding data are
analyzed with the computer program LIGAND and the non-
specific binding is defined as a factor proportional to ‘H-ligand
concentration ( 10). We also further demonstrated that another
(3-adrenergic receptor ligand, [H]CGP-12177, does not suffer
from the additional labeling of the serotonergic site and that it
can be used to selectively measure [3-adrenergic receptors,
whether its nonspecific binding is defined by alprenolol or by
LIGAND.
One of the major premises of current psychopharmacology is
that the /3-adrenergic receptor down-regulation is in some way
related to the therapeutic mechanism of action of antidepres-
sants, because both responses require that antidepressants be
given for a number of days before the response is apparent (1-
4). Indeed, previous studies investigating the down-regulation
of /3-adrenergic binding, using F H]DHA as a radioligand, have
demonstrated that at least 1 week of treatment (in general) is
required to down-regulate the “(3-adrenergic receptor” binding
sites. Indeed, in the present studies, if [ H]DHA binding is
characterized in the typical manner, with nonspecific binding
defined by 10 MM alprenolol, we also found that a significant
decrease in its binding was not apparent until after 7 days of
DM1 treatment (Fig. 1). However, ifthe specific binding of [:IH]
DHA to only f3-adrenergic receptors was measured (with the
LIGAND program defining the nonspecific binding), a signifi-
cant decrease in f3-adrenergic receptors was apparent 24 hr
after a single injection of DM1 (Fig. 1). The decrease in /3-
adrenergic receptors required time to occur, because the effect
was not apparent 2 hr after the DM1 injection. Furthermore,
using the specific /3-adrenergic receptor radioligand [H]CGP-
12177, we were also able to demonstrate a significant decrease
in /3-adrenergic receptors 24 h after a single injection of DM1
(Fig. 2). Using [‘HIDHA as ligand, the decrease seen after a 7-
day versus a 1-day treatment with DM1 was not significantly
greater. However, using [‘H]CGP-12177 as radioligand, it was
apparent that the decrease at 7 days was greater than the
decrease seen at earlier time points. A very early study (21)
using another 13-adrenergic receptor ligand, [‘ 221]iodohydroxy-
benzylpindolol, also reported a significant decrease of /3-adre-
nergic receptors after a single DM1 injection, which became
maximal after seven daily injections.
It has previously been reported that the time course of the
decrease in /3-adrenergic receptors in the hippocampus was
slower than that in the cortex, suggesting that the hippocampus
may be a more primary site for the antidepressant action of
DM1 (22). However, in our study we found that the hippocam-
pus also showed a significant decrease in f3-adrenergic receptors
24 hr after a single DM1 injection and that the pattern of
modifications observed in rat hippocampal membranes resern-
bled those observed in rat cerebral cortex (Fig. 2). As reported
previously (4), no change was detected in /3-adrenergic receptors
after a 7-day treatment with DM1 in striatal membranes from
the same rats. We found that the effects of DM1 occurred solely
at the f3,- and not the /32-athenergic receptor subtype (Fig. 3),
as previously reported (23).
Two studies were undertaken to investigate the role of sero-
tonergic mechanisms in the action of DM1 on f3-adrenergic
receptors. Because DM1 is also a potent inhibitor of 5HT
reuptake and because its chronic administration has also been
reported to down-regulate 5HT2 receptors in rat brain (18), in
one experiment ketanserin, a 5HT, receptor antagonist, was
co-administered with DM1 to investigate whether the blockade
of the effects of endogenous 5HT at 5HT2 receptors would
modulate the ability of DM1 to down-regulate /3-adrenergic
receptors. Irrespective of whether ketanserin was administered
by intraperitoneal injection or was continuously infused by an
implanted osmotic minipump, ketanserin had no influence on
the /3-adrenergic receptor down-regulation by DM1.
We confirmed the down-regulation of 5HT2 receptors elicited
by chronic DM1 treatment (18) and found that the time course
for this effect was somewhat slower than for the down-regula-
tion of /3-adrenergic receptors, becoming significant only at day
4. The chronic administration of ketanserin significantly down-
regulated 5HT2 receptors, as has been reported previously (19).
Interestingly, the effect of ketanserin was not additive with the
effect of DM1, suggesting that possibly both effects are me-
diated by a similar mechanism. However, it is also possible that
there is a ‘ceiling’ effect on the ability of 5HT2 receptors to
down-regulate and that, although ketanserin and DM1 may
work by different mechanisms, only the same maximal down-
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Desipramine Regulation of fi-Adrenergic Receptors 217
regulation can occur. Dose-response studies are needed to re-
solve this question.
It has been reported previously that serotonin depletion,
following the administration of the tryptophan hydroxylase
inhibitor PCPA (5, 6) or lesion of serotonergic forebrain sys-
terns with the neurotoxin 5,7-dihydroxytryptamine (7, 8), is
able to block the ability of DM1 to down-regulate /3-adrenergic
receptors. Moreover PCPA treatment (6) and 5,7-dihydroxy-
tryptamine lesion (8, 9, 24) alone have been shown to increase
the  of [:IHIDHA Indeed, if the /3-adrenergic receptor
binding of [:iH]DHA was defined in the typical way using 10
MM alprenolol, we replicated these observations and found that
“/3-adrenergic receptor” binding was not decreased following 8
days of DM1 treatment if tryptophan hydroxylase had been
inhibited by more than 90% by PCPA treatment and that
PCPA treatment alone significantly increased [‘H]DHA bind-
ing. However, if the selective binding of [‘H]DHA to fl-ache-
nergic receptors was resolved by the computer program LI-
GAND or if fl-adrenergic receptors were investigated with the
selective ligand [‘H]CGP-12177, with nonspecific binding de-
fined by 10 MM alprenolol, we found that PCPA, which alone
did not change the B,,, of /3-adrenergic receptors, was not able
to block the ability of DM1 to down-regulate /3-adrenergic
receptor binding. When either [:iH]CGp42177 or [‘H]DHA
(with nonspecific binding defined by LIGAND) was used as
radioligand, the data suggest that there may have been a
tendency for the PCPA treatment to reduce the effect of DM1,
although the decrease of fl-adrenergic receptors following DM1
under the influence of PCPA was not statistically significantly
different from that after the DM1 treatment alone. However,
this observation may not indicate a role of serotonin in this
effect, because PCPA has also been shown to reduce, although
to a lesser extent, norepinephrine levels (25), which may have
influenced the effect of DM1.
The fact that PCPA treatment increased [‘H]DHA binding
when nonspecific binding was defined by 10 MM alprenolol,
whereas the “true” fl-adrenergic receptors (see above) were not
changed, suggests that PCPA treatment increased the seroto-
nergic component of [‘H]DHA binding. Indeed, ifone subtracts
the true /3-adrenergic receptor binding levels of [‘H]DHA (de-
fined by LIGAND) from the [‘H]DHA binding defined by 10
MM alprenolol, one can derive apparent values for the seroto-
nergic component of [‘H]DHA binding. If this is done, it is
apparent that DM1 itself also increases the binding to the
serotonergic component (+15%). This observation would ex-
plain why a longer time course may be required for the effect
of DM1 on the fl-adrenergic receptor binding of [‘H]DHA
(defined in the typical manner) to become apparent, because
DM1 is simultaneously increasing the serotonergic component
as it is decreasing the /3-adrenergic receptor component of [‘H]
DHA binding.
As already mentioned, there is some controversy in the
literature on the time course of fl-adrenergic receptor down-
regulation following the administration of DM1. A number of
early studies utilized weeks of DM1 treatment, although it is
not clear from the papers whether earlier time points were
adequately examined (1, 2), because more rapid effects have
now been reported by the same laboratories (9). However, a
few reports have indicated that DM1 can down-regulate /3-
adrenergic receptors after a 2-day treatment (3, 21, 22), even
when [‘H]DHA was used as ligand (3, 22). In these two studies,
a single and low concentration of [ H]DHA and/or a lower
concentration of nonradioactive drug to define nonspecific
binding were used. This would tend to more selectively label [3-
adrenergic receptors and to lessen the confounding increase in
the serotonergic component of [‘H]DHA binding sites that we
have shown is simultaneously produced by DM1. Higher con-
centrations of [‘H]DHA will label more of the serotonergic
binding sites, which, as we have shown in the accompanying
paper, bind [‘H]DHA with a lower affinity.
As we discussed in the accompanying paper, it is impossible
to successfully quantify [:H1DHA binding to the non-$-adre-
nergic receptor binding site. We attempted to characterize the
increase in the serotonergic binding component induced by
DM1 and PCPA by analyzing the competition curves of the
semiselective 5HT,, agonist CGS-12066B for [‘H]DHA bind-
ing. In our previous studies, we had demonstrated that this
agonist demonstrates two components of inhibition of [ H]
DHA binding, with a high affinity component of approximately
10-20% of total 2.0 nM [‘H]DHA binding, representing its
competition for the serotonergic component of [‘H]DHA bind-
ing. However, in the present study, the binding of CGS-12066B
in control tissue could not be resolved into two sites in every
animal. When the competition curves for all six control animals
were analyzed simultaneously by the program LIGAND, the
binding could be resolved significantly into two components.
Under these circumstances, with the experimental data from
all rats from each drug treatment analyzed simultaneously, we
found that DM1 and PCPA increased the serotonergic compo-
nent of [:H]DHA binding by 118% and 71%, respectively. The
combined treatment also increased the serotonergic component
of [‘H]DHA by a similar percentage (data not shown). However,
given all the assumptions necessary for this analysis, such as
the approximation of the affinity of [‘H]DHA for the seroto-
nergic component (as detailed in Ref. 10) this result needs to
be confirmed with a selective ‘H-ligand for this site.
The present results suggest that the serotonergic system does
not play a major role in the down-regulation of [3-adrenergic
receptors by DM1. This finding complements the observation
that the effects of DM1 on (3-adrenergic receptor agonist stim-
ulation of adenylate cyclase is also not influenced by serotonin
depletion (8, 9). Moreover, these results may provide an alter-
native interpretation of the recent data from Sulser and co-
workers (26). Under the common assay procedure for [‘H]DHA
binding (nonspecific binding defined by 10 MM propranolol),
they have shown that the increase of [‘H]DHA B,,. after the
lesion of the serotonergic system with 5,7-dihydroxytryptamine
was confined to the /3-adrenergic population that displayed low
affinity for isoproterenol and that this increase could be blocked
by the addition of serotonin to the incubation mixture. In the
previous paper, we have shown that isoproterenol competes for
[‘H]DHA (although not for the specific (3-adrenergic receptor
ligand [“H]CGP-12177) binding in a biphasic manner but that
its low affinity site probably defines the serotonergic binding
site labeled by [‘H]DHA, rather than a low affinity agonist
state of the /3-adrenergic receptor (10). This suggests that the
increase in [“HJDHA binding after serotonin lesion that was
observed by Sulser and co-workers (26) could be due to an
increase in the serotonergic binding site labeled by [ ‘H]DHA
rather than to a change in a low affinity agonist state of the (3-
adrenergic receptor. Similar observations of the ability of 5-
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HT to interact with [ H]DHA binding sites have been made
recently by Dhawan and Kellar (27).
Early studies reported that prolonged treatment with DM1
(4-8 weeks) was necessary to desensitize (3-adrenergic stimu-
lation of adenylate cyclase activity (1). Similarly, early studies
also reported that “weeks” of treatment with DM1 were required
to down-regulate [H]DHA-labeled (3-adrenergic receptors (2,
4). These observations led to the current hypothesis that /3-
adrenergic receptor down-regulation is related to the therapeu-
tic efficacy of antidepressants, which also has a slow onset. In
recent years, however, the effects of DM1 on [3-adrenergic
receptor stimulation of adenylate cyclase have been seen after
only 1 week of treatment by the same laboratories (9), whereas
the early work of other laboratories that reported significant
desensitization after only 1 (21) or a few days (3) of treatment
have not been emphasized. In our study, we find that the down-
regulation of (3-adrenergic receptors can occur 24 hr after a
single injection of DM1. These results suggest that a similarity
in time course of action cannot be used to support the hypoth-
esis that the therapeutic action of DM1 is related to (3-adrener-
gic receptor down-regulation.
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